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O-GlcNAc* Corresponding author. Tel.: +1 778 782 3530; fax
E-mail address: dvocadlo@sfu.ca (D.J. Vocadlo).Increasing cellular O-GlcNAc levels through pharmacological inhibition of O-GlcNAcase, the enzyme
responsible for removal of the O-GlcNAc post-translational modification, is being increasingly used to
aid in discerning the roles played by this form of intracellular glycosylation. Interestingly, two forms
of O-GlcNAcase have been studied; a full-length isoform that is better characterized, and a shorter
nuclear-localized variant, arising from failure to splice out one intron, which has not been as well char-
acterized. Given the increasing use of O-GlcNAcase inhibitors as research tools, we felt that a clear under-
standing of how these inhibitors affect both isoforms of O-GlcNAcase is important for proper
interpretation of studies making use of these inhibitors in cell culture and in vivo. Here we describe an
enzymatic characterization of the nuclear variant of human O-GlcNAcase. We find that this short nuclear
variant of O-GlcNAcase, which has the identical catalytic domain as the full-length enzyme, has similar
trends in a pH-rate profile and Taft linear free energy analysis as the full-length enzyme. These findings
strongly suggest that both enzymes use broadly similar transition states. Consistent with this interpreta-
tion, the short isoform is potently inhibited by several previously described inhibitors of full-length O-
GlcNAcase including PUGNAc, NAG-thiazoline, and the selective O-GlcNAcase inhibitor NButGT. These
findings contrast with earlier studies and suggest that studies using O-GlcNAcase inhibitors in cultured
cells or in vivo can be interpreted with the knowledge that both these forms of O-GlcNAcase are inhibited
when present.1. Introduction
Within higher eukaryotes, numerous nucleocytoplasmic pro-
teins are post-translationally modified with N-acetylglucosamine
(GlcNAc) residues O-linked to certain serine or threonine residues
(O-GlcNAc).1,2 Unlike glycosylation occurring within the secretory
pathway, O-GlcNAc is a dynamic modification similar in some
ways to phosphorylation; the modification can be cleaved off and
reinstalled from the polypeptide backbone more quickly then the
protein is turned over.3,4 Two enzymes are involved in regulating
the dynamic cycling of O-GlcNAc. O-GlcNAc transferase (OGT)5 in-
stalls O-GlcNAc at appropriate serine or threonine residues of tar-
get proteins, whereas O-GlcNAcase (OGA)6 acts to remove the
modification and returns residues to their unmodified state. The
catalytic mechanism of FL-OGA has been shown to proceed in
two steps, via an oxazoline intermediate, to yield the b-anomer
of the free GlcNAc hemiacetal.7 This catalytic mechanism, and for-
mation of the oxazoline intermediate, relies on the involvement of
the 2-acetamido group of the substrate (Fig. 1a). In the first step of
the reaction, this group acts as a nucleophile to attack the anomeric: +1 778 782 3765.center and displace the leaving group. One enzymic carboxylate
(Asp174) likely acts as a general base to enhance nucleophilicity
of the acetamido group while another enzymic carboxylic acid
(Asp175) acts as a general acid catalyst to facilitate departure of
the leaving group.8,9 The second step of the reaction is the near
microscopic reverse of the first step; attack of water at the anomer-
ic center is facilitated by an enzymic base (Asp175) and the acet-
amido group is expelled from the anomeric center with Asp174
likely acting as a general acid. How these catalytic activities of
OGT and OGA are regulated within cells is slowly emerging10,11
and shorter isoforms of both enzymes that stem from alternative
splicing have been described.12–14 Although these shorter isoforms
have only been partially characterized, they have been reported to
have altered properties such as catalytic activity, substrate speci-
ficity, and cellular localization.14–17
The gene encoding O-GlcNAcase (MGEA5) was shown by
Comptesse et al. to undergo alternative splicing to generate a trun-
cated protein.14 When intron 10 fails to be spliced out, a transcript
is generated that encodes a protein having a 662 amino acid N-ter-
minal section identical to the full-length protein (OGA-FL) and an
additional 15 amino acid C-terminal piece arising from the start
of intron 10 (Fig. 1b). Such a protein (OGA-NV) therefore lacks
the C-terminal domain of OGA. This C-terminal domain has been
Figure 1. The catalytic domain responsible for O-GlcNAcase activity is present in both the nuclear variant (OGA-NV) and the full-length form of OGA (OGA-FL). (A) The
proposed catalytic mechanism of OGA involves a two-step double displacement mechanism involving the transient formation of an oxazoline intermediate. Asp174 likely acts
in the first step as a general base, orienting and enhancing the nucleophilicity of the 2-acetamido group toward the anomeric center. Departure of the leaving group is aided
by Asp175, which acts as a general acid catalyst. The second step of the reaction is the near microscopic reverse of the first step; water acts as a nucleophile to attack the
anomeric center and open the oxazoline ring. (B) Schematic showing the architecture of OGA-NV. OGA-NV lacks a putative histone acetyl transferase (HAT) C-terminal
domain. In addition, the OGA-NV contains an additional 15 amino acids (filled black box) encoded by part of intron 10, which is not spliced out in this isoform. (C) Sequence
alignment of the GH84 catalytic domain of OGA-FL (meningioma expressed antigen 5, NP_036347), OGA-NV (meningioma expressed antigen 5, NP_036347), and a bacterial
homologue of O-GlcNAcase from B. thetaiotamicron (BtGH84) (hyaluronoglucosaminidase precursor, NP_813306). Highlighted in light gray are residues that are within 8 Å of
NAG-thiazoline in a structure with BtGH8422 (PDB 2CHO) and residues highlighted in darker gray are those that make contacts (<4 Å) with NAG-thiazoline. Notably, the active
site residues are completely conserved between the three enzymes. Sequence alignment was performed using ClustalW.33
1080reported to have histone acetyl transferase (HAT) activity,18
although more recent efforts have failed to support these find-
ings.19 Cell fractionation studies provided evidence that OGA-NV
resides in the nucleus,14 whereas OGA-FL is predominantly cyto-
solic.20 Unexpectedly, OGA-NV was reported to have no detectable
glycoside hydrolase activity toward the chromogenic substrate
p-nitrophenyl 2-acetamido-2-deoxy-b-D-glucopyranoside (pNP-
GlcNAc)17 but could be assayed with a more sensitive fluorogenic
substrate.17 Furthermore, OGA-NV was shown to be active on
O-GlcNAc-modified proteins, albeit at a diminished rate compared
to OGA-FL.17 More recently it was reported that OGA-NV was
not inhibited by two inhibitors of OGA-FL; O-(2-acetamido-2-deoxy-D-glycopyranosylidene)amino-N-phenylcarbamate (PUG-
NAc, Fig. 2a) and 1,2-dideoxy-20-methyl-a-D-glucopyranoso-[2,1-
d]-D20-thiazoline (NAG-thiazoline, Fig. 2b).21 While these two
inhibitors have nanomolar potencies against OGA-FL,7 it was re-
ported that OGA-NV was only inhibited 50% when they were used
at a concentration of 0.5 mM.21 Based on these studies it was pro-
posed that the active site of OGA-NV may differ from that of OGA-
FL.21 These discrepancies between OGA-FL and OGA-NV in activity
and susceptibility to inhibition are important in the context of
defining the functional roles of these two isoforms in biological
systems. Because these isoforms of OGA may have different, or
compensatory, functional roles, the inhibition of only one of them
Figure 2. Structures of several O-GlcNAcase inhibitors tested in this study. (A)
PUGNAc, (B) NAG-thiazoline, (C) NButGT. While PUGNAc and NAG-thiazoline also
inhibit other functionally related enzymes, NButGT is highly selective for O-
GlcNAcase.
1081could therefore lead to different effects then when inhibiting both
these isoforms.
Based on structural studies of a bacterial homologue of OGA
from Bacteroides thetaiotamicron (BtGH84)22 and the common con-
servation of all the active site residues of OGA-FL, OGA-NV, BtGH84
(Fig. 1c) we were surprised by the apparent 10,000-fold decrease in
affinity toward these inhibitors reported previously, as well as the
decreased catalytic efficiency of OGA-NV relative to OGA-FL. To ad-
dress this apparent discrepancy, we therefore cloned OGA-NV,
characterized the enzymatic properties of this enzyme using vari-
ous assays, and determined its affinity to several known OGA-FL
inhibitors.
2. Results and discussion
2.1. Initial characterization of MBP-tagged OGA-NV
Previously, reports have suggested that OGA-NV has no appar-
ent activity toward pNP-GlcNAc.17 Using purified recombinant
MBP-tagged OGA-NV we found, with careful measurement and
using concentrated enzyme, detectable activity that could be read-
ily described by Michaelis–Menten kinetics (Fig. 3). This OGA-NV
construct bearing a maltose-binding protein affinity tag showed
comparable kinetics to the more poorly expressing OGA-NV con-
struct bearing a His6-tag (data not shown); indicating that the
presence of the MBP on OGA-NV does not significantly impair
catalysis. Although the KM was only increased twofold (OGA-NV
KM = 0.32 ± 0.05 mM; OGA-FL KM = 0.16 ± 0.02 mM), Vmax was de-Figure 3. Michaelis–Menten kinetics for the two isoforms of OGA; OGA-FL and
OGA-NV. Inset is zoomed in view showing the activity of OGA-NV. The kinetic
parameters for OGA-FL are: Vmax = 1.3 lmol min1 mg1; KM = 0.16 mM, whereas
OGA-NV has the following kinetic parameters: Vmax = 0.007 lmol min1 mg1;
KM = 0.32 mM. Therefore, the catalytic efficiency (Vmax/KM) of OGA-NV is approx-
imately 400-fold lower than that of OGA-FL when using pNP-GlcNAc as the
substrate. Data are the average of triplicate rate measurements and error bars
represent standard deviations.creased 200-fold for OGA-NV (OGA-NV Vmax = 0.007 ± .001 lmoles
min1 mg1) as compared to OGA-FL (OGA-FL Vmax = 1.3 ± 0.1
lmoles min1 mg1). Therefore, the catalytic efficiency of OGA-
NV is approximately 400-fold lower than OGA-FL when using
pNP-GlcNAc as a substrate. Although we were able to assay the
enzyme using this substrate, an extremely large concentration of
enzyme (>5 lM) was required to obtain significant rates. Such high
concentrations of enzyme are undesirable when testing potent
inhibitors as they prevent accurate measurement of KI values of
less than fivefold the enzyme concentration. We therefore resorted
to a continuous fluorescence-based assay. Using 4-MU-GlcNAc as
the substrate we were able to use much less enzyme (100 nM) in
our reactions. Michaelis–Menten parameters were obtained using
this substrate and a similar difference (400-fold) in catalytic
efficiencies between OGA-FL and OGA-NV was obtained (data not
shown). It should also be noted that a construct of O-GlcNAcase
consisting of residues 1–662 but lacking the extra 15 amino acids
from intron 10 had a similar decrease in catalytic efficiency,
suggesting that these amino acids do not alter the catalytic
properties of OGA-NV (data not shown). These data support previ-
ous observations that the activity of OGA-NV is significantly
impaired.14,17
2.2. Further enzymatic characterization of OGA-NV
To further characterize OGA-NV we next analyzed its pH-rate
profile. This rate profile was very similar to that observed previ-
ously for OGA-FL9 with an activity maximum of pH 6.5 and a broadFigure 4. Further enzymatic characterization of OGA-NV. (A) The pH-rate profiles
of OGA-FL and OGA-NV reveal a similar shape using 4-MU-GlcNAc as the substrate.
(B) OGA-FL and OGA-NV were tested using a series of four different 4-MU-GlcN-
Acyl substrates that have various degrees of fluorination (0, 1, 2, or 3) on the methyl
group of the 2-acetamido group. The resulting logarithm of the second order rate
constants (Vmax/KM) was plotted as function of the Taft electronic parameter r*. The
similar slopes (q) of these Taft plots imply a similar degree of acetamido
participation, suggesting that the two enzymes use broadly similar transition
states. Data points in panel A represent the average of two measurements. Error
bars in panel B represent the error of the data fit used to obtain the Vmax/KM values.
1082bell-shape (Fig. 4a). The similarity in the shape of the pH-rate pro-
file suggests that the molecular architecture of the O-GlcNAcase
active site is not significantly disrupted in the nuclear variant
OGA-NV. We also carried out a linear free energy analysis using
substrates with different levels of fluorination on the 2-acetamido
group of 4-MU-GlcNAc. As previously described,7 this Taft analysis
correlates the effect of an electronic parameter for the correspond-
ing 2-acetamido group (r*) to the logarithm of the second order
rate constant (log (kcat/KM)).
Glycosidases that use substrate-assisted catalysis display nega-
tive slopes in such Taft analyses due to the involvement of this
moiety as a nucleophile during catalysis to form a transient oxaz-
oline intermediate.7,23 Accordingly, the second order rate constant
for the hydrolysis of a series of fluorinated 4-MU-GlcNAc sub-
strates was measured using OGA-NV and plotted against the Taft
electronic parameter r* to give a negative slope (q) of
0.51 ± 0.07 (Fig. 4b). We previously reported a q-value of 0.42
for OGA-FL, however, a pH of 6.5 was used in those assays.7 The
current studies with OGA-NV were carried out at a more physio-
logically relevant pH of 7.4 and we therefore repeated the study
at this pH with OGA-FL, which gave us a q-value of 0.59 ± 0.06
(Fig 3b). Because these q-values report on the aspects of the struc-
ture of the transition state, particularly the involvement of the
acetamido group as a nucleophile, the statistically indistinguish-
able q-values for the two isoforms strongly suggest that they carry
out catalysis via broadly similar transition states.
Therefore, despite OGA-NV and OGA-FL very likely having iden-
tical active site structures and using similar transition states, there
is still a 400-fold difference in catalytic efficiency between the two
isoforms. It is difficult to ascertain the basis for this difference,
however, we cannot rule out the possibly that the C-terminal do-
main plays a role in facilitating catalysis directly, enzyme stability,
or enzyme dynamics. This view seems consistent with a recent re-
port demonstrating that the C-terminal domain appears to rescue
the catalytic activity of the N-terminal domain when added
in vitro to enzyme assays.19 Given these observations we felt it
would be worthwhile examining whether some of the established
and more widely used inhibitors of OGA-FL were potent against
OGA-NV, which would be expected based on the above-mentioned
results, or whether some of these were genuinely poor inhibitors of
OGA-NV as previously reported.21
2.3. Inhibition of OGA-NV
Two classes of inhibitors of OGA-FL have been fairly well charac-
terized and are used more widely. The first described inhibitor of
OGA-FL was PUGNAc6 (Fig. 2a) and it has been widely used as a
means of elevating O-GlcNAc levels in a cellular context.24 Unfortu-
nately, PUGNAc lacks selectivity for OGA over the functionally re-
lated lysosomal b-hexosaminidases17 and some of the phenotypes
associated with using PUGNAc may not stem from elevation of O-
GlcNAc levels.7,25 More recently, we found7 that NAG-thiazoline
(Fig. 2b)26 is a potent inhibitor of OGA. Like PUGNAc, NAG-thiazo-
line has a nanomolar affinity toward OGA-FL but it is equally potent
against the lysosomal b-hexosaminidases.7 To circumvent this
problematic lack of selectivity for OGA, we generated a series of
selective inhibitors related to NAG-thiazoline and we were able to
realize up to 35,000-fold selectivity for OGA-FL.7,27 One such selec-
tive inhibitor, NButGT (Fig. 2c), is proving to be a useful tool for
studying the biological role of the O-GlcNAc modification.25
Given the effectiveness of these particular inhibitors in modu-
lating OGA-FL activity in vitro,6,7 in cell culture,7,24 tissues studied
ex vivo,28 and in vivo27,29 we felt it is important to clarify their tar-
gets. This is particularly important as a previous study reported
that PUGNAc and NAG-thiazoline are poor inhibitors of OGA-
NV,21 a finding that seems difficult to reconcile with the high levelof conservation of the GH84 catalytic domain (and complete con-
servation of the active site) coupled to the similar trends in the
pH-rate profiles and Taft analyses. Indeed, these data argue that
the two isoforms carry out catalysis via similar transition states
and therefore, given that NAG-thiazoline has been shown to act
as a transition state analogue,30 it was surprising to us that it
was reportedly ineffective against OGA-NV. Such an inability to in-
hibit OGA-NV could complicate the interpretation of data obtained
using these inhibitors in cell culture because OGA-NV and OGA-FL
may have different, or compensatory, physiological roles.
We therefore tested PUGNAc and NAG-thiazoline as inhibitors
of OGA-NV and found that, at a concentration of 500 nM, they re-
sulted in approximately 50% inhibition when using a substrate
concentration of 0.25 mM. Due to the requirement for substantial
amounts of enzyme (100 nM) in our fluorogenic assay, we were
however unable to determine an accurate KI value, although these
data suggest that these inhibitors are similarly potent against OGA-
NV as OGA-FL. To evaluate this issue more carefully we therefore
turned our attention to the selective inhibitor NButGT as it is
slightly less potent (KI = 600 nM). We find that NButGT is a good
inhibitor of OGA-NV and it shows a clear pattern of competitive
inhibition (Fig. 5a and b). The KI value (1.5 ± 0.3 lM) (Fig. 5c) we
determine is only approximately threefold higher than that ob-
served for OGA-FL (KI = 600 nM for OGA-FL) at the same pH.7 We
also tested the product of the reaction (GlcNAc) as an inhibitor of
OGA-NV and found a KI value of 3.6 ± 0.5 mM (Fig. 5d–f), which
is again approximately threefold higher than that reported previ-
ously for OGA-FL (KI = 1.5 mM for OGA-FL).7 This slightly weaker
binding may be consistent with the twofold increased in KM exhib-
ited by OGA-NV. The discrepancy between our results and those
obtained previously by others21 could stem from a number of com-
plicating factors, perhaps most notably is that crude Escherichia coli
extracts containing overexpressed OGA-NV were used in those
studies rather than purified protein that we use here. As a conse-
quence, the concentration of OGA-NV in assays from that earlier
study may have been high and precluded accurate determination
of KI values. Further complicating the use of bacterial lysates in
these inhibition assays is that E. coli has a functionally related b-
N-acetylglucosaminidase known as NagZ, which will readily cleave
b-O-linked glucosaminide substrates.31 The presence of NagZ may
give rise to an overestimate of O-GlcNAcase activity in these
assays.17,213. Conclusions
In summary, careful analyses reveal that OGA-NV has kinetic
properties similar to OGA-FL except that the catalytic efficiency
of OGA-NV is 400-fold lower than that found for OGA-FL. Further-
more, OGA-NV carries out catalysis through transition states that
resemble those used by OGA-FL and both isoforms use the same
catalytic mechanism. Consistent with this view, OGA-NV is also
powerfully inhibited by the same inhibitors that inhibit OGA-FL
indicating that NButGT, and very likely other inhibitors selective
for human OGA over the lysosomal hexosaminidases, will act to
block the activities of both these isoforms. These findings indicate
that inhibition of OGA in cell culture and in vivo using these inhib-
itors likely does not permit functional compensation of OGA-FL
inhibition by continued action of OGA-NV.4. Experimental
4.1. General
All salts and buffers were obtained from Bioshop. Substrates
were obtained from Sigma. Activity assays with pNP-GlcNAc were
Figure 5. NButGT is a potent inhibitor of OGA-NV. Inhibition studies of OGA-NV using NButGT (A–C) and GlcNAc (D–F) as inhibitors. Michaelis–Menten (A, D) and
Lineweaver–Burk plots (B, E) reveal a clear pattern of competitive inhibition. Replots of the apparent KM versus inhibitor concentration (C, F) reveal KI values of 1.5 lM and
3.6 mM for NButGT and GlcNAc, respectively. Data points in panels A, B, D, and E represent the average of triplicate measurements. Error bars are not shown for purposes of
clarity. Error bars in panels C and F represent the errors in KM(apparent) values obtained from fitting of full Michaelis–Menten kinetic data (shown in panels A and D) at each
inhibitor concentration.
1083monitored using a UV–vis spectrophotometer (Cary 3E UV–vis)
and assays with 4-methylumbelliferyl 2-acetamido-2-deoxy-
b-D-glucopyranoside (4-MU-GlcNAc) were monitored using a
fluorimeter (Varian CARY Eclipse). The preparation of PUGNAc,32
NAG-thiazoline,26 and 1,2-dideoxy-20-propyl-a-D-glucopyranoso-
[2,1-d]-D20-thiazoline (NButGT)7 has been described elsewhere.
4-MU-GlcNAc substrates bearing varying levels of fluorination on
the 2-acetamido group were prepared as described previously.7
4.2. Cloning
OGA-NV contains 15 amino acids that are encoded by the start
of intron 10. Because these nucleotides are not available within a
cDNA clone of OGA, they were incorporated within primers using
two successive rounds of PCR. For the first round of PCR, the for-
ward and reverse primers were: 50-GCCGCCCATATGGTGCAGAAGG
AGAGTCAAGCG-30 and 50-GCCGCCCTCGAGGAAGAGATTATTCCTG
GTGCACCTACCTAACCACTGTACAAAA-GAC-30, respectively. This
PCR product was used in a second round of PCR using the same for-
ward primer but with the reverse primer: 50GCCGCCCTCGAGTT
AAAGGGACAATATAT-TTGAGGAGAAGAGATTATTCCTGGTGCACC-30.
This elongated PCR product was ligated into pET28a (Novogen)
using the NdeI and XhoI restriction sites to generate a His6-tagged
fusion protein, however, yields of the resulting recombinant pro-
tein were very low (data not shown). We therefore subsequently
subcloned OGA-NV into the pMal-C2X vector using the SalI and
BamHI restriction sites to produce a construct encoding a protein
bearing an N-terminally fused maltose binding protein (MBP).
4.3. Expression and purification
The pMal-C2X vector (New England Biolabs) containing OGA-
NV was transformed into tuner BL21 DDE3 cells (Novagen) forexpression. Cells were induced with 0.5 mM IPTG when the
OD600 of the culture reached 0.8. After 3 h of induction at room
temperature, cells were pelleted by centrifugation (5000 rpm,
10 min) and resuspended in PBS containing 1 mM EDTA. Cells were
lysed using a combination of incubation with 1 mg/ml lysozyme
for 30 min at room temperature as well as sonication (6 cycles,
20 s, 50% duty). The cell debris was pelleted by centrifugation
(15,000 rpm, 1 h) and the supernatant was loaded onto a 5 ml Dex-
trin Sepharose column (GE Healthcare), washed with 100 ml of PBS
containing 1 mM EDTA, and eluted in 25 ml of PBS containing
20 mM maltose. The fractions containing purified OGA-NV were
concentrated to a volume of 2 ml and loaded onto a gel filtration
chromatography on a Sephacryl S-300 size-exclusion column (GE
Healthcare). Fractions containing OGA-NV were identified by
SDS–PAGE as well as by fluorescence-activity assays (see below),
pooled, and then dialyzed against PBS. Purification of OGA-FL has
been described previously.8
4.4. Kinetics
Initial rates of hydrolysis of pNP-GlcNAc and 4-MU-GlcNAc
were measured as described previously.8,27 The pH-rate profile
was carried out in buffer containing 50 mM citric acid, 50 mM so-
dium phosphate, 50 mM CHES, and 100 mM sodium chloride ad-
justed to the appropriate pH. The extinction coefficient at each
respective pH was determined using the Beer–Lambert law by
measuring the absorbance of several concentrations of p-nitro-
phenolate in the appropriate buffer. To quantitate turnover of 4-
MU-GlcNAc a standard curve was constructed bracketing the range
of fluorescence measurements made during enzyme activity as-
says. The Taft analysis was carried out by continuous monitoring
of the liberated 4-methylumberlliferone product using PBS (pH
7.4) as a buffer.
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